Latest Arteriocyte Stories
CLEVELAND, July 20, 2011 /PRNewswire/ -- ArteriocyteÂ®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies announced today that the Ohio Department of Development's Third Frontier Commission awarded a $1 million grant to the company for its "Development and Commercialization of Hematopoietic Stem Cell Expansion for Clinical Applications" as part of the Ohio...
American scientists have developed â€œartificial bloodâ€ that could soon be used to treat soldiers who are wounded during battle.
Arteriocyte, a clinical stage biotechnology company announced today that the company has been awarded $496,000 through the Global Cardiovascular Innovation Center (GCIC), to continue clinical research on its lead stem cell therapy (ACY001) for use in chronic coronary ischemia.
Arteriocyte, a clinical stage biotechnology company, has received a fast track Phase I/II small business innovation research grant award from the National Heart, Lung, and Blood Institute, of the National Institutes of Health.
Arteriocyte, a clinical stage biotechnology company announced today the receipt of a fast track Phase I/II Small Business Innovation Research Grant Award (R44HL092706-01) from National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health (NIH).
- Large; stout; burly.